ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Pharmaceutical Nanotechnology: What To Know

  Here is what you need to know about the key advantages that pharmaceutical nanotechnology provides in improving drug efficacy and decreasing adverse reactions.

• Supporting Complex Manufacturing For Liquid And Lyophilized Drug Products

  Aseptic fill and finish operations gain efficiency and precision with modular isolator technology, inline weight checks, and lyophilization, which are ideal for mRNA-LNPs and other sensitive modalities.

• Is The Autoinjector Dead? The Future Of Patient-Centered Drug Delivery

  Autoinjectors revolutionized drug delivery, but innovation is shifting toward oral, wearable, and alternative platforms. Future focus emphasizes patient experience, sustainability, and broader drug delivery toolkits beyond the autoinjector.

• Streamlining The Path To Market For Generic Drug-Device Combinations

  Developing g-DDCPs is a complex and time-consuming process. By using a risk-based approach, manufacturers can streamline the development process and bring g-DDCPs to market more quickly.

• When Glass Vials Fail At Low Temps, Consider A Cyclic Olefin Polymer System

  If the glass vial for a biologic drug experiences breakage, or does not maintain container closure integrity, a cyclic olefin polymer (i.e., Daikyo Crystal Zenith COP) system may be the solution.

• Data-Driven Approach Optimizes Robust, Scalable Lyophilization Process

  Selecting the right manufacturing partner with appropriate lyophilization expertise, experience, and analytical capabilities can speed drug development and expedite time to market for lyophilized drugs.

• Gamification: The Answer To Pharma's Non-Adherence Crisis?

  Digital connectivity is transforming the consumer experience and digital technology can now improve the patient experience too, in ways that were just not possible before.

• Selecting Drug Delivery Systems For Higher Doses, Viscosities And Lower Risk

  Discover how companies can de-risk their device selection as they bring this new generation of high-volume, high-viscosity biologics to market.

• Managing Poor Solubility With Cutting-Edge Formulation Approaches

  An increasing number of poorly soluble APIs are the cornerstone of cutting-edge therapies, necessitating equally complex formulation technologies to maintain or improve solubility and, ultimately, bioavailability.

• Advancements In GLP-1 Analog Formulation: Overcoming Challenges

  Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment to offer improved patient comfort and adherence while expanding the therapeutic market.